Abemaciclib for malignant pleural mesothelioma – Authors' reply

• Published in: The lancet oncology Vol. 23; no. 6; p. e238
• Main Authors: Fennell, Dean A, Nusrat, Nada
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-06-2022; Elsevier Limited
• Subjects: Cytotoxicity; Hypotheses; Mesothelioma; Tumors
• ISSN: 1470-2045; 1474-5488
• DOI: 10.1016/S1470-2045(22)00285-6

Addition mechanisms of tumour–suppression might involve the PRMT5–MDM4–p53 axis or enhanced tumour immunity.3 To clarify for readers, the original link between PRMT5 and 9p21 deletion was reported by three independent groups in 2016 who showed a synthetic lethal relationship between MTAP and PRMT5.4 In MiST2, MTAP expression correlated with response rate by an unknown mechanism, which is under investigation. Published individual patient meta-analyses have clearly shown a significant association between DCR and overall survival for cytotoxic therapies.5 The efficacy of ipilimumab and nivolumab (DCR of 50% at 12 weeks of 58% in the MAPS2 trial, now licensed for use in the first-line) and CONFIRM trial (50%, and the first trial to show improved survival in the relapsed setting), reinforcing our hypothesis and use of a DCR of 50% at 12 weeks as a trial endpoint. DAF reports grants from Astex Therapeutics, personal fees from Aldeyra, grants from Boehringer Ingelheim, non-financial support from Clovis, Eli Lilly, and BMS, personal fees from Inventiva and RS Oncology, personal fees, and non-financial support from Roche, grants from MSD and Bayer, personal fees from Atara, Targovax, and Lab21, during the conduct of the study; and grants, personal fees, and non-financial support from BMS, outside the submitted work.